Results 191 to 200 of about 1,067,356 (214)

Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer. [PDF]

FASEB Bioadv
Molczyk C, Sturgeon R, Saxena S, Johnson E, Bhatia R, Bhyravbhatla N, Kumar S, Batra SK, Singh RK.   +8 more
europepmc   +1 more source

Immunotherapy in endometrial cancer: mechanisms, clinical evidence, and future directions. [PDF]

Front Immunol
Lian M, Zhang C, Li T, Wang A.
europepmc   +1 more source

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. [PDF]

Cancer Discov
Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Rüttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H.   +25 more
europepmc   +1 more source

PRSS22 promotes the immune evasion of gastric cancer via inhibiting ANXA1-mediated degradation of PD-1. [PDF]

Food Nutr Res
Wang J, Zhou J, Chen X.
europepmc   +1 more source

Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions. [PDF]

Ann Med
Song R, Li M, Tang S, Zhang G.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

Ca-A Cancer Journal for Clinicians, 2023
Balazs Dome
exaly  

Brain and other central nervous system tumor statistics, 2021

Ca-A Cancer Journal for Clinicians, 2021
Kimberly D Miller, Quinn T Ostrom, Carol Kruchko Ba   +2 more
exaly